Shareholder Johnson & Johnson bought stock in the molecular diagnostics technology provider as it floated in Brussels at a valuation of more than $500m.
Biocartis, a Belgium-based molecular diagnostics company backed by several corporates, has raised €100m ($111m) from an initial public offering in Brussels, floating at the top of its range.
The company issued almost 8.7 million shares on the Euronext Brussels market priced at €11.50 per share. The IPO valued it at €450m.
Founded in 2007, Biocartis is developing molecular diagnostics technology centred on its IdyllaTM platform that can provide real-time molecular information from any biological sample.
Half the IPO proceeds will…
